Drug intelligence / Profile preview

RGI-3100

Development stage: Preclinical
Lead developer: REGiMMUNE
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

RGI-3100 is an antigen-specific liposomal immunotherapy from REGiMMUNE's reVax platform, designed to induce immune tolerance for type 1 diabetes (T1D) by pharmacologically promoting regulatory T cells (Tregs). It combines α-galactosylceramide (α-GalCer), a CD1d ligand and activator of invariant natural killer T (iNKT) cells, with T1D target antigens such as insulin B peptide encapsulated in liposomes to restore immune balance, potentially preventing or delaying T1D onset without broad immunosuppression. Developed in collaboration with JDRF and Pfizer, preclinical studies in NOD mice demonstrated prevention of spontaneous T1D development and reduction of islet inflammation.[1][3][4][5]

Other names: RGI-3100-iBRGI3100-iBRGI 3100-iB

Targets

iNKT TCR (Invariant natural killer T-cell receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on RGI-3100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGI-3100.

Explore the full profile